Search
Menu
Home
HTB
2009
October
HTB
October 2009
Contents
Editorial
Volume 10 Number 9/10 September/October 2009
Conference reports
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town
First results of new integrase compound: GSK1349572
Raltegravir in treatment-naive patients
Nevirapine vs atazanavir/ritonavir in treatment-naive patients: ARTEN study
Darunavir/r monotherapy studies
Maraviroc results similar to efavirenz when analysed using more sensitive tropism test
Lipid and metabolic changes with ARV combinations
Maximal suppression achieved with three drugs: no additional virological impact of raltegravir intensification
Tenofovir and renal safety
Time from seroconversion to treatment in Europe and Africa
Pharmacokinetics of atazanavir/ritonavir during pregnancy
Presentation with late stage HIV in women diagnosed during pregnancy
Low transmission rates and favourable pregnancy outcomes reported in the DREAM study
Pregnancy rates and outcomes among women in the DART trial
Pregnancy outcomes in HAART exposed infants in Johannesburg
Efavirenz conceptions in Soweto
Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg
A cost-effectiveness analysis of the OCTANE trial
The PEARL study
Results from HSV-2 acyclovir studies
Overview of TB-related studies at IAS
Antiretrovirals
CD4 responses after viral suppression for more than 7 years on HAART
Raltegravir approved in Europe for treatment-naive patients
50mg and 100mg ritonavir doses achieve similar levels of saquinavir in Thai patients
Etravirine (Intelence) label change in the US due to severe hypersensitivity reactions
PK and drug interactions
Raltegravir trough levels reduced by etravirine may require use of TDM
Lopinavir/r affects PK exposure of some antimalarial drugs
Darunavir/r increases exposure to nevirapine
Interaction between Ginkgo biloba and efavirenz
Use of raltegravir in HIV-positive transplant recipients
Basic science and immunology
Trends in Immunology: free access issue on immune senescence
Low viral loads in elite controllers
Immune surveillance below the radar: study offers explanation for acyclovir’s failure to reduce HIV risk
Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption
BHIVA news
Detention and removal of HIV-positive people in the UK
Correspondence
Letter: comment on swine flu algorithm
On the web
5th IAS Conference on HIV Pathogenesis, Treatment and Prevention abstracts
Access to HCV treatment in Eastern Europe
Guide to HIV and hepatitis B coinfection
TAG pipeline report
New TB website and resource
HIV and the kidneys
Video news: online resource
PDFs
Volume 10 Number 9/10 September/October 2009 PDF
HTB RSS
Early access
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024
i-Base guides updated online
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate